We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) recently announced an agreement to acquire Invuity Inc. for approximately $190 million. This buyout is expected to augment Stryker’s surgical portfolio, thereby aiding the core Neurotechnology & Spine segment. The deal is expected to close in the fourth quarter of 2018.
Following the announcement, shares of Stryker inched up 0.9% to $171.76 at close. In the past year, the stock has rallied 19.6% compared with the industry’s 18.2% rise. The current level is also higher than the S&P 500 index’s increase of 16.2%.
California-based Invuity offers innovative products for minimally-invasive surgery, in which Stryker specializes. The combined leadership is thus likely to equip Stryker to ensure better patient outcomes.
Notably, this will boost the Neurotechnology & Spine division which includes both neurosurgical and neurovascular devices. In the last reported quarter, this segment accounted for 19.2% of total revenues. The segment also grew 12% organically.
Per a study by Transparency Market Research, the global surgical instruments market is estimated to register revenues worth $11.28 billion by the end of 2019. The market is likely to be dominated by Europe and North America geographies, which see robust demand for surgical instruments.
Inside Stryker’s Surgical Suite
Stryker offers a wide array of products across all three of its core units, viz, Orthopaedic, MedSurg and Neurotechnology & Spine.
Some of the major surgical products include AIM laparoscopes, AHTO Pump, CrossFlow Tubing, Fluid Safe fluid management system and Precision AC.
Stryker’s coveted Mako robotic-arm assisted surgery platform also deserves a mention here. Recently, the company launched the robotic-arm assisted total knee arthroplasty application for use with its Mako System.
In fact, in the last reported quarter, Stryker’s instruments revenues improved 12.6% at constant currency.
Want More From the MedTech Space?
A few better-ranked stocks from the broader medical space are athenahealth , Intuitive Surgical (ISRG - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock sports a Zacks Rank #2 (Buy).
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio
Stryker Corporation (SYK - Free Report) recently announced an agreement to acquire Invuity Inc. for approximately $190 million. This buyout is expected to augment Stryker’s surgical portfolio, thereby aiding the core Neurotechnology & Spine segment. The deal is expected to close in the fourth quarter of 2018.
Following the announcement, shares of Stryker inched up 0.9% to $171.76 at close. In the past year, the stock has rallied 19.6% compared with the industry’s 18.2% rise. The current level is also higher than the S&P 500 index’s increase of 16.2%.
The stock currently has a Zacks Rank #3 (Hold).
Recently, Stryker announced the buyout of K2M Group Holdings for $1.4 billion with a view to boost its Spine business. (Read More: Stryker to Acquire K2M Group, Fortify Spine Division)
How Will Stryker Gain?
California-based Invuity offers innovative products for minimally-invasive surgery, in which Stryker specializes. The combined leadership is thus likely to equip Stryker to ensure better patient outcomes.
Notably, this will boost the Neurotechnology & Spine division which includes both neurosurgical and neurovascular devices. In the last reported quarter, this segment accounted for 19.2% of total revenues. The segment also grew 12% organically.
Per a study by Transparency Market Research, the global surgical instruments market is estimated to register revenues worth $11.28 billion by the end of 2019. The market is likely to be dominated by Europe and North America geographies, which see robust demand for surgical instruments.
Inside Stryker’s Surgical Suite
Stryker offers a wide array of products across all three of its core units, viz, Orthopaedic, MedSurg and Neurotechnology & Spine.
Some of the major surgical products include AIM laparoscopes, AHTO Pump, CrossFlow Tubing, Fluid Safe fluid management system and Precision AC.
Stryker’s coveted Mako robotic-arm assisted surgery platform also deserves a mention here. Recently, the company launched the robotic-arm assisted total knee arthroplasty application for use with its Mako System.
In fact, in the last reported quarter, Stryker’s instruments revenues improved 12.6% at constant currency.
Want More From the MedTech Space?
A few better-ranked stocks from the broader medical space are athenahealth , Intuitive Surgical (ISRG - Free Report) and Masimo Corporation (MASI - Free Report) .
athenahealth has a long-term expected earnings growth rate of 17.6%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock sports a Zacks Rank #2 (Buy).
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>